Articles Related to Cyclosporine
Successful Treatment of Acquired Amegakaryocytic Thrombocytopenia (AAT) with Cyclosporine and Eltrombopag: A Case Report
Acquired amegakaryocytic thrombocytopenia is an unusual hematological disorder characterized by severe thrombocytopenia in association with a marked decrease, or the absence, of megakaryocytes in bone marrow. Its pathogenesis is not well understood and its clinical course is variable. Several treatments have been used, producing different responses. We present a case that was successfully treated with a calcineurin inhibitor combined with a thrombopoiesis-stimulating agent.
Generalized pustular psoriasis (GPP) is an acute and uncommon form of psoriasis, representing about 3% of all psoriasis cases. Triggers may include streptococcical infections, emotional stress, vaccinations and exposure to medications such as penicillin. Systemic therapy is often necessary for GPP, since it may rapidly evolve, leading to significant and potentially fatal complications. Here, we describe the case of a 5-year-old male presenting with diffuse erythema, confluent scaly plaques and painful pustules localized on the trunk and limbs. Systemic manifestations such as fever, general lymphadenopathy and arthritis were also observed. To date, no standardized treatment guideline exists for infantile acute generalized pustular psoriasis. Our patient responded successfully to cyclosporine treatment within 4 weeks without any side effects. Thus, cyclosporine could be considered a useful agent in cases of pediatric GPP, keeping in mind its side effect profile in child population.
Atopic dermatitis, also known as eczema, affects about 10-20% of children in the UK and about 1-3% of adults . The incidence of atopic dermatitis has increased as much as 3 fold in the past 40 years
Drug Tolerability and Outcomes in Kidney Transplant Recipients Treated with Two Formulations of Mycophenolic Acid
Mycophenolic Acid (MPA) is one of the most widely used immunosuppressive agents in kidney transplantation. This study was designed to compare the safety, tolerability and efficacy of two formulations of mycophenolic acid, Mycophenolate Mofetil (MMF) and Enteric-Coated Mycophenolate Sodium (EC-MPS), in renal transplant recipients.